Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Clinician differences in attitudes and perceptions on the use of long-acting injectable antipsychotic agents in treating patients with schizophrenia: results from the US DECIDE survey.
BMC Psychiatry
March 2025
Teva Branded Pharmaceutical Products R&D, Inc., North America Medical Affairs, Parsippany, NJ, USA.
Background: Long-acting injectable antipsychotics (LAIs) reduce relapses in schizophrenia; however, most clinicians reserve LAIs for nonadherence with oral antipsychotics (OAs) or severe disease.
Methods: US psychiatric clinicians were surveyed regarding their schizophrenia management practices and use of LAIs. Respondents were grouped by LAI use (high [≥ 31% of patients using LAIs], low [≤ 14% using LAIs]; mid not analyzed) and mindset based on their response to "Which of the following best fits the current way you view your use of [LAIs] for your patients with schizophrenia?"
Results: Respondents (n = 380) were distributed across LAI use (106 high, 130 low) and mindset (123 early-use, 88 severity-reserved, 113 adherence-reserved, 56 LAI-hesitant) subgroups.
Paliperidone-induced neuroleptic malignant syndrome: A case report.
Medicine (Baltimore)
March 2025
Clinic of Psychiatry, Mersin Sehir Egitim ve Arastirma Hastanesi, Toroslar, Mersin, Turkey.
Rationale: Neuroleptic malignant syndrome (NMS) is a rare, life-threatening complication of neuroleptic (antipsychotic) medications. Paliperidone is an atypical antipsychotic used in the treatment of schizophrenia. While current evidence suggests that atypical oral antipsychotics have a lower incidence of NMS compared to typical oral antipsychotics, there is limited information available on the incidence and management of NMS associated with long-acting injectable (LAI) antipsychotics.
View Article and Find Full Text PDFRelationship between cognitive impairments and psychopathological symptoms in female schizophrenia subsequent to 8 weeks treatment with antipsychotic drugs.
BMC Psychiatry
March 2025
Department of Psychiatry, the Affiliated Brain Hospital of Nanjing Medical University, Nanjing Brain Hospital, Nanjing, 210029, China.
Background: Changes in cognitive impairments and their relationship with psychopathological symptoms during treatment in schizophrenia remain debatable. Especially, there is few studies specifically focusing on female patients. Further exploration of the characteristics of female schizophrenia patients can offer valuable sex-related considerations for clinicians in diagnosis and interventions.
View Article and Find Full Text PDFPredictors of clozapine concentration and psychiatric symptoms in patients with schizophrenia.
PLoS One
March 2025
Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Clozapine has superior efficacy to other antipsychotics, especially in patients with treatment-resistant schizophrenia. However, its pharmacokinetics and pharmacodynamics vary largely among patients. We aimed to evaluate the clinical and genetic factors associated with the pharmacokinetics and pharmacodynamics of clozapine in patients with schizophrenia.
View Article and Find Full Text PDF[Clinical and immunological relationships in patients with early schizophrenia].
Zh Nevrol Psikhiatr Im S S Korsakova
March 2025
Psycho-Neurological Dispensary No. 1, St. Petersburg, Russia.
Objective: To study clinical and immunological relationships in patients with early schizophrenia during remission.
Material And Methods: Forty-eight patients (53% females and 47% males) were examined at the initial stage of schizophrenia during remission (age 28.3±5.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!